StockMacro
Company, fund or insider

Help

Menu

Ultragenyx Pharmaceutical

$16.48 -29% in 6 monthsMarket cap $1.7B

RARE on XNAS, Health Care, Ultragenyx Pharmaceutical Inc., job postings

Measures activity, not value. Not investment advice.

Revenue grew 16% to $730.3M but the stock fell 47% over 12 months while 23% of shares are shorted.

  • BadNet loss of $523.6M over the last 12 months
  • BadInstitutional holders fell 13% to 263 from 304

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Industry
Pharmaceutical preparations (Health Care)
Employees
1,371
Website
ultragenyx.com
Listed
Nasdaq, US
Last results
3 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $173.0M, net loss $118.0M.
Quarter to 31 Dec 2021: revenue $83.4M, net income -$122.5MQuarter to 31 Dec 2021: revenue $83.4M, net income -$122.5MQuarter to 31 Mar 2022: revenue $79.9M, net income -$152.3MQuarter to 31 Mar 2022: revenue $79.9M, net income -$152.3MQuarter to 30 Jun 2022: revenue $89.3M, net income -$158.2MQuarter to 30 Jun 2022: revenue $89.3M, net income -$158.2MQuarter to 30 Sep 2022: revenue $90.7M, net income -$245.1MQuarter to 30 Sep 2022: revenue $90.7M, net income -$245.1MQuarter to 31 Dec 2022: revenue $103.3M, net income -$151.8MQuarter to 31 Dec 2022: revenue $103.3M, net income -$151.8MQuarter to 31 Mar 2023: revenue $100.5M, net income -$164.0MQuarter to 31 Mar 2023: revenue $100.5M, net income -$164.0MQuarter to 30 Jun 2023: revenue $108.3M, net income -$159.8MQuarter to 30 Jun 2023: revenue $108.3M, net income -$159.8MQuarter to 30 Sep 2023: revenue $98.1M, net income -$159.6MQuarter to 30 Sep 2023: revenue $98.1M, net income -$159.6MQuarter to 31 Dec 2023: revenue $127.4M, net income -$123.2MQuarter to 31 Dec 2023: revenue $127.4M, net income -$123.2MQuarter to 31 Mar 2024: revenue $108.8M, net income -$170.7MQuarter to 31 Mar 2024: revenue $108.8M, net income -$170.7MQuarter to 30 Jun 2024: revenue $147.0M, net income -$131.6MQuarter to 30 Jun 2024: revenue $147.0M, net income -$131.6MQuarter to 30 Sep 2024: revenue $139.5M, net income -$133.5MQuarter to 30 Sep 2024: revenue $139.5M, net income -$133.5MQuarter to 31 Dec 2024: revenue $164.9M, net income -$133.4MQuarter to 31 Dec 2024: revenue $164.9M, net income -$133.4MQuarter to 31 Mar 2025: revenue $139.3M, net income -$151.1MQuarter to 31 Mar 2025: revenue $139.3M, net income -$151.1MQuarter to 30 Jun 2025: revenue $166.5M, net income -$115.0MQuarter to 30 Jun 2025: revenue $166.5M, net income -$115.0MQuarter to 30 Sep 2025: revenue $159.9M, net income -$180.4MQuarter to 30 Sep 2025: revenue $159.9M, net income -$180.4MQuarter to 31 Dec 2025: revenue $207.3M, net income -$128.6MQuarter to 31 Dec 2025: revenue $207.3M, net income -$128.6MQuarter to 31 Mar 2026: revenue $136.0M, net income -$185.0MQuarter to 31 Mar 2026: revenue $136.0M, net income -$185.0MQuarter to 30 Jun 2026: revenue $214.0M, net income -$92.0MQuarter to 30 Jun 2026: revenue $214.0M, net income -$92.0MQuarter to 30 Sep 2026: revenue $173.0M, net income -$118.0MQuarter to 30 Sep 2026: revenue $173.0M, net income -$118.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $245.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$173.0M-$118.0M
30 Jun 2026$214.0M-$92.0M
31 Mar 2026$136.0M-$185.0M
31 Dec 2025$207.3M-$128.6M
30 Sep 2025$159.9M-$180.4M
30 Jun 2025$166.5M-$115.0M
31 Mar 2025$139.3M-$151.1M
31 Dec 2024$164.9M-$133.4M
30 Sep 2024$139.5M-$133.5M
30 Jun 2024$147.0M-$131.6M
31 Mar 2024$108.8M-$170.7M
31 Dec 2023$127.4M-$123.2M
30 Sep 2023$98.1M-$159.6M
30 Jun 2023$108.3M-$159.8M
31 Mar 2023$100.5M-$164.0M
31 Dec 2022$103.3M-$151.8M
30 Sep 2022$90.7M-$245.1M
30 Jun 2022$89.3M-$158.2M
31 Mar 2022$79.9M-$152.3M
31 Dec 2021$83.4M-$122.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $730.3M $630.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +16% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$523.6M -$579.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$5.18 -$5.93
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -64.0% -86.3% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -71.7% -91.8% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$450.6M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $266.0M $425.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$266.0M (net cash) -$425.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.3 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.9 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Ultragenyx PharmaceuticalRARE (this company) $1.7Bloss2.3+16%-71.7%
Agios PharmaceuticalsAGIO $1.7Bloss11.7+214%-265%
Korsana BiosciencesKRSA $1.7Bloss–––
SchrodingerSDGR $1.7Bloss6.4+4.8%-22.0%
Zenas BioPharmaZBIO $1.6Bloss–––
First Tracks BiotherapeuticsTRAX $1.7B––––

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+8.2%

$173.0M vs $159.9M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$128K

bought $0, sold $128K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-13%

263 13F filers vs 304

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

102.7M shares held by 13F filers (30 Sep 2026) of 101.9M outstanding (29 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

23%

23.6M shares sold short (30 Oct 2026) of 101.9M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.3

23.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+17%

20.1M shares sold short in the report before, 23.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

40%

40% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.2M

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.1×

18 articles in the last 7 days; its usual week has 3.5.

Price $16.48 on 20 Nov 2026, -47% over 12 months (12-month range $12.88 to $36.54)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $3.8M in the last 12 months (the 12 months before: -$8.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, -38% on the 12 months before.
Revenue per quarter. Revenue $173.0M in the latest quarter, +8.2% on a year earlier.
Capital spending per quarter. Capital spending $1.0M in the latest quarter, -24% on a year earlier.
Institutional holders (13F filers). 263 13F filers reported holding it in the latest 13F quarter, -7.4% on a year earlier.
Lobbying spend. Lobbying spend: $1.2M published in the last 12 months, +72% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
3 Nov 20268-K and other filingsCompleted an acquisition or asset sale
3 Nov 20268-K and other filingsRestructuring costs announced
18 Aug 2026Sharp changeShort interest spike: short interest spike, 15.0M vs usual 9.0M (2026-07-31); 2.0x the same period a year earlier
6 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 214.0M vs usual 153.5M (2026-06-30); 1.3x the same period a year earlier
21 Jul 2026Sharp changeLobbying spend jump: lobbying spend jump, 390K vs usual 135K (2026-06-30); 2.8x the same period a year earlier
20 Jul 2026Sharp changeLobbying on a new issue: lobbying on a new issue: GOV, MED (2026-03-31)
13 Jul 2026Lobbying filingnew lobbying registration (ALPINE GROUP PARTNERS, LLC.)
16 Jun 2026Sharp changeShort interest spike: short interest spike, 14.7M vs usual 8.6M (2026-05-29); 2.7x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 14.0M vs usual 8.5M (2026-05-15); 2.4x the same period a year earlier
18 May 20268-K and other filingsDirector or officer change
18 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 May 2026Sharp changeShort interest spike: short interest spike, 13.7M vs usual 8.4M (2026-04-30); 2.5x the same period a year earlier
20 Apr 2026Lobbying filinglobbying engagement terminated (AVIVA STRATEGIES (FKA MGB CONSULTING))
30 Mar 2026Lobbying filingnew lobbying registration (MILLER STRATEGIES, LLC)
12 Feb 20268-K and other filingsRestructuring costs announced
29 Jul 2025Sharp changeShort interest spike: short interest spike, 8.8M vs usual 4.2M (2025-07-15); 2.0x the same period a year earlier
24 May 2025Lobbying filingnew lobbying registration (AVIVA STRATEGIES (FKA MGB CONSULTING))
19 May 20258-K and other filingsDirector or officer change
19 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Feb 2025Sharp changeQuarterly revenue change: quarterly revenue change, 164.9M vs usual 108.6M (2024-12-31); 1.3x the same period a year earlier
12 Nov 2024Sharp changeQuarterly revenue change: quarterly revenue change, 139.5M vs usual 105.8M (2024-09-30); 1.4x the same period a year earlier
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 147.0M vs usual 101.9M (2024-06-30); 1.4x the same period a year earlier
19 Jul 2024Lobbying filingnew lobbying registration (MEHLMAN CONSULTING, INC.)
21 Jun 20248-K and other filingsDirector or officer change
21 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Apr 2024Sharp changeLobbying spend jump: lobbying spend jump, 250K vs usual 50K (2024-03-31); 5.0x the same period a year earlier
1 Apr 2024Lobbying filinglobbying engagement terminated (HASHEMI STRATEGIC ADVISORS)
12 Mar 2024Lobbying filingnew lobbying registration (in-house)
11 Jan 2024Lobbying filinglobbying engagement terminated (FORBES-TATE)
13 Nov 2023Lobbying filingnew lobbying registration (HASHEMI STRATEGIC ADVISORS)
8 Sep 20238-K and other filingsDirector or officer change
12 Jul 20238-K and other filingsDirector or officer change
13 Jun 20238-K and other filingsDirector or officer change
23 Mar 20238-K and other filingsDirector or officer change
14 Mar 20238-K and other filingsDirector or officer change
14 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Nov 20228-K and other filingsDirector or officer change
15 Sep 20228-K and other filingsDirector or officer change
15 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jul 20228-K and other filingsCompleted an acquisition or asset sale
22 Apr 20228-K and other filingsDirector or officer change
22 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2022Lobbying filinglobbying engagement terminated (THE KPM GROUP DC LLC)
19 Jan 2022Lobbying filinglobbying engagement terminated (CROSSROADS STRATEGIES, LLC)
Insider net buying (open market)
Month from 1 Feb 2022: -$110K published
Month from 1 Mar 2022: -$2.4M published
Month from 1 Apr 2022: -$11K published
Month from 1 Jun 2022: -$16K published
Month from 1 Oct 2022: -$199K published
Month from 1 Dec 2022: -$89K published
Month from 1 Jan 2023: -$892K published
Month from 1 Mar 2023: -$794K published
Month from 1 May 2023: -$298K published
Month from 1 Jun 2023: -$91K published
Month from 1 Jul 2023: -$27K published
Month from 1 Sep 2023: -$352K published
Month from 1 Oct 2023: -$2.9M published
Month from 1 Jan 2024: -$1.4M published
Month from 1 Feb 2024: -$1.4M published
Month from 1 Mar 2024: -$2.0M published
Month from 1 Apr 2024: -$6K published
Month from 1 May 2024: -$15K published
Month from 1 Jun 2024: -$513K published
Month from 1 Jul 2024: -$24K published
Month from 1 Aug 2024: -$1.0M published
Month from 1 Sep 2024: -$1.1M published
Month from 1 Oct 2024: -$394K published
Month from 1 Dec 2024: -$414K published
Month from 1 Jan 2025: -$495K published
Month from 1 Mar 2025: -$6.8M published
Month from 1 May 2025: -$29K published
Month from 1 Jun 2025: -$90K published
Month from 1 Sep 2025: -$81K published
Month from 1 Oct 2025: -$250K published
Month from 1 Dec 2025: -$115K published
Month from 1 Jan 2026: -$72K published
Month from 1 Feb 2026: -$72K published
Month from 1 Mar 2026: -$2.5M published
Month from 1 Apr 2026: -$98K published
Month from 1 May 2026: -$269K published
Month from 1 Jun 2026: -$207K published
Month from 1 Jul 2026: -$156K published
Month from 1 Aug 2026: -$164K published
Month from 1 Sep 2026: -$20K published
Month from 1 Oct 2026: -$108K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 3 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 8 published
Quarter from 1 Oct 2022: 3 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 6 published
Quarter from 1 Oct 2023: 4 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 3 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 2 published
Quarter from 1 Apr 2025: 4 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 3 published
Revenue per quarter
Quarter ended 31 Dec 2021: $83.4M, -8.9% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $79.9M, -20% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $89.3M, +2.7% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $90.7M, +11% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $103.3M, +24% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $100.5M, +26% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $108.3M, +21% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $98.1M, +8.1% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $127.4M, +23% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $108.8M, +8.3% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $147.0M, +36% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $139.5M, +42% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $164.9M, +29% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $139.3M, +28% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $166.5M, +13% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $159.9M, +15% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $207.3M, +26% on a year earlier; public on 19 Feb 2026
Quarter ended 31 Mar 2026: $136.0M, -2.4% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $214.0M, +29% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $173.0M, +8.2% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $16.0M, -27% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $32.2M, +96% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $30.9M, +54% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $26.0M, +27% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $27.0M, +68% on a year earlier; public on 18 Feb 2023
Quarter ended 31 Mar 2023: $25.0M, -22% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $13.9M, -55% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $3.7M, -86% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $1.6M, -94% on a year earlier; public on 22 Feb 2024
Quarter ended 31 Mar 2024: $3.2M, -87% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $2.0M, -86% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $1.6M, -56% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $654K, -59% on a year earlier; public on 20 Feb 2025
Quarter ended 31 Mar 2025: $1.3M, -59% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $2.5M, +22% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $1.3M, -21% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $1.0M, -24% on a year earlier; public on 7 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 217; public on 14 Feb 2022
31 Mar 2022 report: 224; public on 16 May 2022
30 Jun 2022 report: 207; public on 15 Aug 2022
30 Sep 2022 report: 211; public on 14 Nov 2022
31 Dec 2022 report: 209; public on 14 Feb 2023
31 Mar 2023 report: 215; public on 15 May 2023
30 Jun 2023 report: 221; public on 14 Aug 2023
30 Sep 2023 report: 205; public on 14 Nov 2023
31 Dec 2023 report: 224; public on 14 Feb 2024
31 Mar 2024 report: 260; public on 15 May 2024
30 Jun 2024 report: 258; public on 14 Aug 2024
30 Sep 2024 report: 288; public on 14 Nov 2024
31 Dec 2024 report: 303; public on 14 Feb 2025
31 Mar 2025 report: 290; public on 15 May 2025
30 Jun 2025 report: 301; public on 14 Aug 2025
30 Sep 2025 report: 284; public on 14 Nov 2025
31 Dec 2025 report: 275; public on 17 Feb 2026
31 Mar 2026 report: 288; public on 15 May 2026
30 Jun 2026 report: 304; public on 14 Aug 2026
30 Sep 2026 report: 263; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $100K published
Quarter from 1 Apr 2022: $50K published
Quarter from 1 Jul 2022: $50K published
Quarter from 1 Oct 2022: $50K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $79K published
Quarter from 1 Apr 2024: $250K published
Quarter from 1 Jul 2024: $30K published
Quarter from 1 Oct 2024: $80K published
Quarter from 1 Jan 2025: $110K published
Quarter from 1 Apr 2025: $330K published
Quarter from 1 Jul 2025: $140K published
Quarter from 1 Oct 2025: $140K published
Quarter from 1 Jan 2026: $130K published
Quarter from 1 Jul 2026: $830K published
Quarter from 1 Oct 2026: $280K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $280K (30 Sep 2026), 2.0× its normal reading; higher than 89% of its own history. Two or more unrelated kinds of activity agreed on 6 Aug 2026.
  • Short interest spike: had 14.0M shares sold short in the 15 May 2026 report, 2.4× the same report last year Public on 28 May 2026.
  • Lobbying spend jump: reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year Public on 20 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $3.8M in the last 12 months (the 12 months before: -$8.2M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 3 sales, $128K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Oct 2026Howard HornChief Financial OfficerSell7,066$15.27$108KForm 4
15 Sep 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerSellplanned in advance (10b5-1)1,283$13.57$17KForm 4
8 Sep 2026Theodore Alan HuizengaSVP, Chief Accounting OfficerSell161$13.99$2KForm 4
4 Aug 2026Karah Herdman ParschauerEVP and Chief Legal OfficerSellplanned in advance (10b5-1)1,900$24.92$47KForm 4
4 Aug 2026Howard HornChief Financial OfficerSellplanned in advance (10b5-1)4,696$24.92$117KForm 4
6 Jul 2026Howard HornChief Financial OfficerSellplanned in advance (10b5-1)4,698$33.13$156KForm 4
15 Jun 2026Corazon (Corsee) D. SandersDirectorSell2,000$25.05$50KForm 4
15 Jun 2026Karah Herdman ParschauerEVP and Chief Legal OfficerSellplanned in advance (10b5-1)1,899$24.62$47KForm 4

263 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 40 opened a position, 76 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.11.4M11.2%$171.8M+779K+7.3%
RTW Investments, LP8.5M8.37%$128.2M+732K+9.4%
Vanguard Portfolio Management LLC8.4M8.26%$126.5M+1.6M+24%
State Street Corp7.5M7.40%$113.3M+1.4M+22%
Vanguard Capital Management LLC4.3M4.22%$64.6M+2,677+0.1%
Two Sigma Investments, LP3.1M3.07%$47.1M-491K-14%
Jacobs Levy Equity Management, Inc2.9M2.85%$43.6M-39K-1.3%
Nantahala Capital Management, LLC2.3M2.30%$35.2MNew+2.3M
GW&K Investment Management, LLC2.3M2.26%+827K+56%
Geode Capital Management, LLC2.2M2.13%$32.7M-405K-16%

Company events

All 47 company events

In 12 months: 2 restructurings, 2 major agreements, 1 director or officer change, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
3 Nov 2026Completed an acquisition or asset sale; Restructuring costs announced8-K
14 Oct 2026Signed a major agreement8-K
7 Oct 2026Signed a major agreement8-K
18 May 2026Director or officer changeSame filing: shareholder vote results8-K
12 Feb 2026Restructuring costs announced8-K
4 Nov 2025Signed a major agreement8-K
19 May 2025Director or officer changeSame filing: shareholder vote results8-K
21 Jun 2024Director or officer changeSame filing: shareholder vote results8-K

Reported lobbying spend: $280K in Q3 2026, $390K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Aug 2026EndedForbes-Tatefor Ultragenyx PharmaceuticalIssues related to drug development and market access.Health issuesFiling
1 Mar 2026NewMiller Strategies, LLCfor Ultragenyx Pharmaceutical Inc.Issues relating to rare disease and patient access.MEDFiling
3 Feb 2026NewAlpine Group Partners, LLC.for Ultragenyx Pharmaceutical Inc.Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)Health issues, Government issues, MEDFiling
5 Jan 2026EndedAviva Strategies (Fka MGB Consulting)for Ultragenyx Pharmaceuticaln/a termination reportHealth issuesFiling
2 May 2025NewAviva Strategies (Fka MGB Consulting)for Ultragenyx PharmaceuticalRare & ultra-rare disease policy issues, newborn screening, genomic sequencingHealth issuesFiling
1 Jul 2024NewMehlman Consulting, Inc.for Ultragenyx Pharmaceutical, Inc.Issues related to rare disease drug development and access; coverage for genetic testing; and newborn screening.Health issues, Budget, Medicare/MedicaidFiling
15 Mar 2024NewUltragenyx Pharmaceutical Inc.its own lobbyistsIssues related to drug development, access and reimbursement for rare and ultrarare diseases.Health issues, Budget, Medicare/MedicaidFiling
11 Mar 2024EndedHashemi Strategic Advisorsfor UltragenyxLHHS; Rare and Ultrarare diseases Orphan Drug Act (DOA) Pediatric Priority Review Voucher (PPRV); Rare and Ultrarare genetic diseases; Medicare and MedicaidBudget, Health issues, MED, Medicare/MedicaidFiling

The 5 newest of 237 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

6 Aug 2026confirmed

Confirmed across sources Filings + Financials and Lobbying and Short interest and volume

Ultragenyx Pharmaceutical (RARE): reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year; it also reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year; and it had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year. Three unrelated kinds of activity within 29 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Jul 2026
  • Lobbying: Lobbying spend jump, became public on 20 Jul 2026
  • Financials: Quarterly revenue change, became public on 6 Aug 2026
  • Short interest and volume: Short interest spike, became public on 12 Aug 2026
2024-06-30: $30K2024-09-30: $80K2024-12-31: $110K2025-03-31: $330K2025-06-30: $140K2025-09-30: $140K2025-12-31: $130K2026-03-31: $440K2026-06-30: $390K
The quarter ended 30 Jun 2026 against the 8 quarters before it. this quarterearliernormal: $135K
See the evidence (4 changes)

Lobbying: Lobbying on a new issue became public on 20 Jul 2026

Ultragenyx Pharmaceutical lobbying on a new issue.

New
['GOV', 'MED']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4687383

Lobbying: Lobbying spend jump became public on 20 Jul 2026

Ultragenyx Pharmaceutical reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.

This period
$390K (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$135K
Typical spread (median absolute deviation)
$40K
How far from its usual level
+4.3
Same quarter last year
$140K
History used
2,373 days
2024-06-30: $30K2024-09-30: $80K2024-12-31: $110K2025-03-31: $330K2025-06-30: $140K2025-09-30: $140K2025-12-31: $130K2026-03-31: $440K2026-06-30: $390K
the quarter ended 30 Jun 20268 earlier quartersnormal: $135K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Financials: Quarterly revenue change became public on 6 Aug 2026

Ultragenyx Pharmaceutical reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.

This period
$214.0M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$153.5M
Typical spread (median absolute deviation)
$13.5M
How far from its usual level
+3.0
Same quarter last year
$166.5M
History used
3,652 days
2024-06-30: $147.0M2024-09-30: $139.5M2024-12-31: $164.9M2025-03-31: $139.3M2025-06-30: $166.5M2025-09-30: $159.9M2025-12-31: $207.3M2026-03-31: $136.0M2026-06-30: $214.0M
the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 Aug 2026

Ultragenyx Pharmaceutical had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.

This period
15.0M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
9.0M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+3.7
Same report last year
7.6M
History used
3,136 days
2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M2026-05-15: 14.0M2026-05-29: 14.7M2026-06-15: 14.3M2026-06-30: 16.2M2026-07-15: 13.4M2026-07-31: 15.0M
the 31 Jul 2026 report24 earlier reportsnormal: 9.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

10 Dec 2019confirmed

Confirmed across sources Filings + Financials and Lobbying

Ultragenyx Pharmaceutical (RARE): spent $5.0M on capital projects in the quarter ended 30 Sep 2019, 4.9× the same quarter last year, while it registered for federal lobbying for the first time in our data (Forbes-Tate). Two unrelated kinds of activity within 27 days.

  • Financials: Quarterly capital spending jump, became public on 12 Nov 2019
  • Lobbying: First lobbying registration, became public on 10 Dec 2019
2017-09-30: $1.0M2017-12-31: $899K2018-03-31: $475K2018-06-30: $1.4M2018-09-30: $1.0M2018-12-31: $1.2M2019-03-31: $3.1M2019-06-30: $5.2M2019-09-30: $5.0M
The quarter ended 30 Sep 2019 against the 8 quarters before it. this quarterearliernormal: $1.1M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 12 Nov 2019

Ultragenyx Pharmaceutical spent $5.0M on capital projects in the quarter ended 30 Sep 2019, 4.9× the same quarter last year.

This period
$5.0M (the quarter ended 30 Sep 2019)
Normal quarter (median of 8 earlier)
$1.1M
Typical spread (median absolute deviation)
$239K
How far from its usual level
+3.9
Same quarter last year
$1.0M
History used
2,374 days
2017-09-30: $1.0M2017-12-31: $899K2018-03-31: $475K2018-06-30: $1.4M2018-09-30: $1.0M2018-12-31: $1.2M2019-03-31: $3.1M2019-06-30: $5.2M2019-09-30: $5.0M
the quarter ended 30 Sep 20198 earlier quartersnormal: $1.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Lobbying: First lobbying registration became public on 10 Dec 2019

Ultragenyx Pharmaceutical registered for federal lobbying for the first time in our data (Forbes-Tate).

Source coverage starts
5 Jan 2011
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 3 Nov 2026Filings record

    Restructuring costs announced

  2. 3 Nov 2026Filings record

    Completed an acquisition or asset sale

  3. 12 Aug 2026Short interest and volume change

    had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.

    Same report last year: 7.6M; its normal report is 9.0M.

    See the evidence
    This period
    15.0M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +3.7
    Same report last year
    7.6M
    History used
    3,136 days
    2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M2026-05-15: 14.0M2026-05-29: 14.7M2026-06-15: 14.3M2026-06-30: 16.2M2026-07-15: 13.4M2026-07-31: 15.0M
    the 31 Jul 2026 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 6 Aug 2026several at once

    reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year; it also reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year; and it had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year. Three unrelated kinds of activity within 29 days.

    See the evidence (4 changes)

    Lobbying: Lobbying on a new issue became public on 20 Jul 2026

    Ultragenyx Pharmaceutical lobbying on a new issue.

    New
    ['GOV', 'MED']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4687383

    Lobbying: Lobbying spend jump became public on 20 Jul 2026

    Ultragenyx Pharmaceutical reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.

    This period
    $390K (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $135K
    Typical spread (median absolute deviation)
    $40K
    How far from its usual level
    +4.3
    Same quarter last year
    $140K
    History used
    2,373 days
    2024-06-30: $30K2024-09-30: $80K2024-12-31: $110K2025-03-31: $330K2025-06-30: $140K2025-09-30: $140K2025-12-31: $130K2026-03-31: $440K2026-06-30: $390K
    the quarter ended 30 Jun 20268 earlier quartersnormal: $135K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Financials: Quarterly revenue change became public on 6 Aug 2026

    Ultragenyx Pharmaceutical reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.

    This period
    $214.0M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $153.5M
    Typical spread (median absolute deviation)
    $13.5M
    How far from its usual level
    +3.0
    Same quarter last year
    $166.5M
    History used
    3,652 days
    2024-06-30: $147.0M2024-09-30: $139.5M2024-12-31: $164.9M2025-03-31: $139.3M2025-06-30: $166.5M2025-09-30: $159.9M2025-12-31: $207.3M2026-03-31: $136.0M2026-06-30: $214.0M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 12 Aug 2026

    Ultragenyx Pharmaceutical had 15.0M shares sold short in the 31 Jul 2026 report, 2.0× the same report last year.

    This period
    15.0M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    1.1M
    How far from its usual level
    +3.7
    Same report last year
    7.6M
    History used
    3,136 days
    2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M2026-05-15: 14.0M2026-05-29: 14.7M2026-06-15: 14.3M2026-06-30: 16.2M2026-07-15: 13.4M2026-07-31: 15.0M
    the 31 Jul 2026 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  5. 6 Aug 2026Financials change

    reported revenue of $214.0M for the quarter ended 30 Jun 2026, 1.3× the same quarter last year.

    Same quarter last year: $166.5M; its normal quarter is $153.5M.

    See the evidence
    This period
    $214.0M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $153.5M
    Typical spread (median absolute deviation)
    $13.5M
    How far from its usual level
    +3.0
    Same quarter last year
    $166.5M
    History used
    3,652 days
    2024-06-30: $147.0M2024-09-30: $139.5M2024-12-31: $164.9M2025-03-31: $139.3M2025-06-30: $166.5M2025-09-30: $159.9M2025-12-31: $207.3M2026-03-31: $136.0M2026-06-30: $214.0M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $153.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 20 Jul 2026Lobbying change

    reported $390K of lobbying spend for the quarter ended 30 Jun 2026, 2.8× the same quarter last year.

    Same quarter last year: $140K; its normal quarter is $135K.

    See the evidence
    This period
    $390K (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $135K
    Typical spread (median absolute deviation)
    $40K
    How far from its usual level
    +4.3
    Same quarter last year
    $140K
    History used
    2,373 days
    2024-06-30: $30K2024-09-30: $80K2024-12-31: $110K2025-03-31: $330K2025-06-30: $140K2025-09-30: $140K2025-12-31: $130K2026-03-31: $440K2026-06-30: $390K
    the quarter ended 30 Jun 20268 earlier quartersnormal: $135K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  7. 20 Jul 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['GOV', 'MED']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4687383
  8. 13 Jul 2026Lobbying record

    ULTRAGENYX PHARMACEUTICAL INC.: new lobbying registration (ALPINE GROUP PARTNERS, LLC.) (dated 3 Feb 2026)

  9. 10 Jun 2026Short interest and volume change

    had 14.7M shares sold short in the 29 May 2026 report, 2.7× the same report last year.

    Same report last year: 5.5M; its normal report is 8.6M.

    See the evidence
    This period
    14.7M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    8.6M
    Typical spread (median absolute deviation)
    971K
    How far from its usual level
    +4.2
    Same report last year
    5.5M
    History used
    3,073 days
    2025-05-30: 5.5M2025-06-13: 6.1M2025-06-30: 6.8M2025-07-15: 8.8M2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M2026-05-15: 14.0M2026-05-29: 14.7M
    the 29 May 2026 report24 earlier reportsnormal: 8.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 28 May 2026Short interest and volume change

    had 14.0M shares sold short in the 15 May 2026 report, 2.4× the same report last year.

    Same report last year: 5.9M; its normal report is 8.5M.

    See the evidence
    This period
    14.0M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    8.5M
    Typical spread (median absolute deviation)
    857K
    How far from its usual level
    +4.3
    Same report last year
    5.9M
    History used
    3,059 days
    2025-05-15: 5.9M2025-05-30: 5.5M2025-06-13: 6.1M2025-06-30: 6.8M2025-07-15: 8.8M2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M2026-05-15: 14.0M
    the 15 May 2026 report24 earlier reportsnormal: 8.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 18 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 18 May 2026Filings record

    Director or officer change

  13. 12 May 2026Short interest and volume change

    had 13.7M shares sold short in the 30 Apr 2026 report, 2.5× the same report last year.

    Same report last year: 5.5M; its normal report is 8.4M.

    See the evidence
    This period
    13.7M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    8.4M
    Typical spread (median absolute deviation)
    729K
    How far from its usual level
    +4.9
    Same report last year
    5.5M
    History used
    3,044 days
    2025-04-30: 5.5M2025-05-15: 5.9M2025-05-30: 5.5M2025-06-13: 6.1M2025-06-30: 6.8M2025-07-15: 8.8M2025-07-31: 7.6M2025-08-15: 8.4M2025-08-29: 8.3M2025-09-15: 7.9M2025-09-30: 7.7M2025-10-15: 8.7M2025-10-31: 7.1M2025-11-14: 7.8M2025-11-28: 8.9M2025-12-15: 8.6M2025-12-31: 8.0M2026-01-15: 8.9M2026-01-30: 9.1M2026-02-13: 9.9M2026-02-27: 9.6M2026-03-13: 9.9M2026-03-31: 11.4M2026-04-15: 12.1M2026-04-30: 13.7M
    the 30 Apr 2026 report24 earlier reportsnormal: 8.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 20 Apr 2026Lobbying record

    ULTRAGENYX PHARMACEUTICAL: lobbying engagement terminated (AVIVA STRATEGIES (FKA MGB CONSULTING)) (dated 5 Jan 2026)

  15. 30 Mar 2026Lobbying record

    ULTRAGENYX PHARMACEUTICAL INC.: new lobbying registration (MILLER STRATEGIES, LLC) (dated 1 Mar 2026)

  16. 12 Feb 2026Filings record

    Restructuring costs announced

  17. 25 Jul 2025Short interest and volume change

    had 8.8M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.

    Same report last year: 4.4M; its normal report is 4.2M.

    See the evidence
    This period
    8.8M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    4.2M
    Typical spread (median absolute deviation)
    677K
    How far from its usual level
    +4.5
    Same report last year
    4.4M
    History used
    2,755 days
    2024-07-15: 4.4M2024-07-31: 4.2M2024-08-15: 3.8M2024-08-30: 3.5M2024-09-13: 3.6M2024-09-30: 2.9M2024-10-15: 3.2M2024-10-31: 3.2M2024-11-15: 3.3M2024-11-29: 3.4M2024-12-13: 3.7M2024-12-31: 4.0M2025-01-15: 4.3M2025-01-31: 4.2M2025-02-14: 4.3M2025-02-28: 4.6M2025-03-14: 4.8M2025-03-31: 4.5M2025-04-15: 5.5M2025-04-30: 5.5M2025-05-15: 5.9M2025-05-30: 5.5M2025-06-13: 6.1M2025-06-30: 6.8M2025-07-15: 8.8M
    the 15 Jul 2025 report24 earlier reportsnormal: 4.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 24 May 2025Lobbying record

    ULTRAGENYX PHARMACEUTICAL: new lobbying registration (AVIVA STRATEGIES (FKA MGB CONSULTING)) (dated 2 May 2025)

  19. 19 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 19 May 2025Filings record

    Director or officer change

  21. 25 Feb 2025Financials change

    reported revenue of $164.9M for the quarter ended 31 Dec 2024, 1.3× the same quarter last year.

    Same quarter last year: $127.4M; its normal quarter is $108.6M.

    See the evidence
    This period
    $164.9M (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    $108.6M
    Typical spread (median absolute deviation)
    $9.3M
    How far from its usual level
    +4.1
    Same quarter last year
    $127.4M
    History used
    3,106 days
    2022-12-31: $103.3M2023-03-31: $100.5M2023-06-30: $108.3M2023-09-30: $98.1M2023-12-31: $127.4M2024-03-31: $108.8M2024-06-30: $147.0M2024-09-30: $139.5M2024-12-31: $164.9M
    the quarter ended 31 Dec 20248 earlier quartersnormal: $108.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 12 Nov 2024Financials change

    reported revenue of $139.5M for the quarter ended 30 Sep 2024, 1.4× the same quarter last year.

    Same quarter last year: $98.1M; its normal quarter is $105.8M.

    See the evidence
    This period
    $139.5M (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    $105.8M
    Typical spread (median absolute deviation)
    $6.6M
    How far from its usual level
    +3.2
    Same quarter last year
    $98.1M
    History used
    3,014 days
    2022-09-30: $90.7M2022-12-31: $103.3M2023-03-31: $100.5M2023-06-30: $108.3M2023-09-30: $98.1M2023-12-31: $127.4M2024-03-31: $108.8M2024-06-30: $147.0M2024-09-30: $139.5M
    the quarter ended 30 Sep 20248 earlier quartersnormal: $105.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 6 Aug 2024Financials change

    reported revenue of $147.0M for the quarter ended 30 Jun 2024, 1.4× the same quarter last year.

    Same quarter last year: $108.3M; its normal quarter is $101.9M.

    See the evidence
    This period
    $147.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $101.9M
    Typical spread (median absolute deviation)
    $6.6M
    How far from its usual level
    +4.4
    Same quarter last year
    $108.3M
    History used
    2,922 days
    2022-06-30: $89.3M2022-09-30: $90.7M2022-12-31: $103.3M2023-03-31: $100.5M2023-06-30: $108.3M2023-09-30: $98.1M2023-12-31: $127.4M2024-03-31: $108.8M2024-06-30: $147.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $101.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 19 Jul 2024Lobbying record

    ULTRAGENYX PHARMACEUTICAL, INC.: new lobbying registration (MEHLMAN CONSULTING, INC.) (dated 1 Jul 2024)

  25. 21 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 21 Jun 2024Filings record

    Director or officer change

  27. 1 Apr 2024Lobbying change

    reported $250K of lobbying spend for the quarter ended 31 Mar 2024, 5.0× the same quarter last year.

    Same quarter last year: $50K; its normal quarter is $50K.

    See the evidence
    This period
    $250K (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    $50K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +10.0
    Same quarter last year
    $50K
    History used
    1,552 days
    2022-03-31: $50K2022-06-30: $50K2022-09-30: $50K2022-12-31: $50K2023-03-31: $50K2023-06-30: $60K2023-09-30: $40K2023-12-31: $79K2024-03-31: $250K
    the quarter ended 31 Mar 20248 earlier quartersnormal: $50K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  28. 1 Apr 2024Lobbying record

    ULTRAGENYX: lobbying engagement terminated (HASHEMI STRATEGIC ADVISORS) (dated 11 Mar 2024)

  29. 12 Mar 2024Lobbying record

    ULTRAGENYX PHARMACEUTICAL INC.: new lobbying registration (in-house) (dated 15 Mar 2024)

  30. 11 Jan 2024Lobbying record

    ULTRAGENYX PHARMACEUTICAL: lobbying engagement terminated (FORBES-TATE) (dated 31 Aug 2026)

  31. 13 Nov 2023Lobbying record

    ULTRAGENYX: new lobbying registration (HASHEMI STRATEGIC ADVISORS) (dated 1 Oct 2023)

  32. 8 Sep 2023Filings record

    Director or officer change

  33. 12 Jul 2023Filings record

    Director or officer change

  34. 13 Jun 2023Filings record

    Director or officer change

  35. 23 Mar 2023Filings record

    Director or officer change

  36. 14 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 14 Mar 2023Filings record

    Director or officer change

  38. 10 Nov 2022Filings record

    Director or officer change

  39. 15 Sep 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 15 Sep 2022Filings record

    Director or officer change

Showing the newest 40 of 81 entries; narrow the window or the kind of data to see older ones.

Not listed: 416 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001515673
Ticker
RARE
Domain
ultragenyx.com
Employer name
Ultragenyx Pharmaceutical, Inc. (1 unverified)
Hq location
CA|NOVATO|94949 (1 unverified)
Lobbying client
ultragenyx, ultragenyx pharmaceutical
Name
Amlogenyx Inc, Rare Delaware Inc, Ultragenyx Argentina SRL, Ultragenyx Brasil Farmacêutica Ltda and 12 more
Uei
MS1ZFMTA7JH7
Wikipedia
Ultragenyx
  • DOL H-1B labor condition applications and PERM certifications309 data points6 Apr 2020 to 27 Jul 2026
  • Federal lobbying disclosures (LDA)14 records, 84 data points16 Oct 2019 to 30 Sep 2026
  • SEC Form 13F institutional holdings459 data points31 Mar 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)227 records25 Feb 2016 to 3 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)883 data points31 Dec 2011 to 29 Oct 2026
  • SEC Form 4 insider transactions219 records, 568 data points4 Jan 2016 to 19 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026